Study #2017-1055
Phase II Study of Cpx-351 in Combination with Venetoclax in Patients with Acute Myeloid Leukemia (AML)
MD Anderson Study Status
Not Accepting
Treatment Agent
Liposome-encapsulated Daunorubicin-Cytarabine, Venetoclax
Description
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Study phase:
Phase II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.